MediPal Holdings Corporation
MediPal Holdings Corporation (MAHLY) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
mahly · pe ratio · data through Mar 31, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for MediPal Holdings Corporation (MAHLY) measures how much investors pay for each dollar of the company's trailing earnings. MAHLY's current PE ratio of 12.77x is calculated by dividing its stock price of $19.30 by its TTM earnings per share of $209.33. +2.3% elevated vs 5Y avg 12.5x
Source: FMP · /ratios-ttm · /analyst-estimates · 2026-03-31
PE Ratio History
2007 – 2026 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 20 fiscal years · Front-end computedMinQ1 · 25%13.9x
MedianQ3 · 75%138.4x
Max
At 12.77x, MAHLY's current P/E is lower than in 25% of its annual fiscal year readings over the past 20 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Medical - Distribution · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
MediPal Holdings CorporationYou MAHLY | $4.0B | 12.77x | -28.5% | $209.33 |
 Alfresa Holdings Corporation ALFRY | $2.5B | 10.58x | -40.8% | $243.49 |
 Ansell Limited ANSLF | $2.8B | 25.74x | +44.1% | $0.70 |
 Ansell Limited ANSLY | $2.8B | 28.42x | +59.1% | $2.80 |
 Gedeon Richter PLC RGEDF | $7.1B | 8.03x | -55.0% | $1263.38 |
 Ryman Healthcare Limited RHCGF | $1.4B | N/A | — | -$0.17 |
 Sundrug Co.,Ltd. SDGCF | $3.6B | 16.56x | -7.3% | $270.05 |
Industry Average 5 peers with valid PE | — | 17.87x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2026-03-31Latest FY2026 | 12.80x | $219.14 | +2.2% | |
2025-03-31 FY2025 | 12.54x | $193.19 | +4.8% | |
2024-03-31 FY2024 | 11.96x | $195.83 | +27.2% | |
2023-03-31 FY2023 | 9.41x | $184.82 | -40.3% | |
2022-03-31 FY2022 | 15.76x | $140.13 | -17.8% | |
2021-03-31 FY2021 | 19.16x | $113.95 | +58.2% | |
2020-03-31 FY2020 | 12.11x | $175.80 | -32.7% | |
2019-03-31 FY2019 | 18.01x | $145.59 | +26.6% | |
2018-03-31 FY2018 | 14.23x | $154.13 | +2.5% | |
2017-03-31 FY2017 | 13.88x | $128.12 | +4.6% |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for MediPal Holdings Corporation (MAHLY) measures how much investors pay for each dollar of the company's trailing earnings. MAHLY's current PE ratio of 12.77x is calculated by dividing its stock price of $19.30 by its TTM earnings per share of $209.33.
Frequently asked questions
MAHLY pe ratio · 6 questionsMAHLY's current PE ratio is 12.77x as of 2026-06-08, based on a stock price of $19.30 and TTM EPS of $209.33. Data sourced from Financial Modeling Prep via MAHLY's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · MediPal Holdings Corporation SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08